摘要:
The present invention relates to the carbocyclic diarylmethylene derivatives of formula (I): ##STR1## and to their use in therapeutics, especially as drugs with anti-inflammatory and analgesic properties.
摘要:
The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially as drugs having antiproliferative properties and affording an effective treatment for diseases such as cancer, psoriasis, atherosclerosis, restenosis phenomena or any other pathological condition due to cell proliferation.
摘要:
The present invention relates to a novel pharmaceutical composition for the preparation of effervescent powders or tablets incorporating ibuprofen or one of its pharmaceutically acceptable salts as the active ingredient.This composition comprises:an effective amount of ibuprofen or one of its pharmaceutically acceptable salts;a pharmaceutically acceptable effervescent system comprising at least one alkaline carbonate and at least one organic acid, preferably in a sufficient amount to give a pH below about 8; andat least one pharmaceutically acceptable antioxidant in a sufficient amount to stabilize the ibuprofen.This composition has a remarkable stability both in powder form and in tablet form.
摘要:
The present invention relates to the derivatives of formula (I): ##STR1## and their addition salts, and to their use in therapeutics, especially for the treatment of cardiovascular diseases and in particular for the treatment of hypertension and cardiac insufficiency.
摘要:
The present invention relates to the derivatives of the formula ##STR1## in which: A is an aromatic ring or a nitrogen heterocycle;X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently a hydrogen atom, a halogen atom, a lower alkyl radical, a C.sub.3 -C.sub.7 cycloalkyl radical, an alkoxy radical, an alkylthio radical, a sulfone group, SO.sub.2 -lower alkyl, a sulfoxide group, SO-lower alkyl, a trifluoromethyl group, a nitro group, a hydroxyl group, a methylene alcohol radical or a group COOR', in which R' is a hydrogen or a lower alkyl; X.sub.3 and X.sub.4 can also form a naphthalene with the phenyl;B is CR.sub.5 R.sub.6, R.sub.5 and R.sub.6 being a hydrogen atom, a lower alkyl or a C.sub.3 -C.sub.7 cycloalkyl radical, or the sulfur atom;R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, a lower alkyl radical or a C.sub.3 -C.sub.7 cycloalkyl radical; CR.sub.1 R.sub.2 or CR.sub.3 R.sub.4 can form with B, when the latter is CR.sub.5 R.sub.6, a cycloalkyl or a cycloalkene having 3 to 7 carbon atoms; R.sub.1 R.sub.2 and R.sub.3 R.sub.4 can also form a ring having 3 to 7 carbon atoms;n is an integer from 1 to 4 and can be 0 if R.sub.1 and R.sub.2 are other than hydrogen; andD is a chemical group which can be: COOR.sub.7, R.sub.7 being the hydrogen atom, a lower alky radical or a C.sub.3 -C.sub.7 cycloalkyl radical, CONH-R.sub.8, R.sub.8 being the hydrogen atom, a lower alkyl radical or a C.sub.3 -C.sub.7 cycloalkyl radical, or CN,and to their addition salts. The compounds are thromboxane antagonist receptors.
摘要:
The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially as drugs with analgesic properties.
摘要:
The present invention relates to the derivatives of the formula ##STR1## and their addition salts, and to their use in therapeutics, especially in the central nervous system as analgesics, anticonvulsants, antiepileptics, anxiolytics, antidepressants and neuroprotectors, and in the cardiovascular system as antiarrhythmics, antihypertensives and platelet aggregation inhibitors.
摘要:
The present invention relates to the derivatives of the formula ##STR1## in which: A is an aromatic ring or a nitrogen heterocycle;X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are independently a hydrogen atom, a halogen atom, a lower alkyl radical, an alkoxy radical, an alkylthio radical, a sulfone group, a sulfoxide group, a trifluoromethyl group, a nitro group, a hydroxyl group, a methylene alcohol radical or a group COOR', in which R' is a hydrogen or a lower alkyl; X.sub.3 and X.sub.4 can also form a naphthalene with the phenyl;B is CR.sub.5 R.sub.6, R.sub.5 and R.sub.6 being a hydrogen atom or a lower alkyl, or the sulfur atom;R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom or a lower alkyl radical; CR.sub.1 R.sub.2 or CR.sub.3 R.sub.4 can form with B, when the latter is CR.sub.5 R.sub.6, a cycloalkyl or a cycloalkene having 3 to 7 carbon atoms; R.sub.1 R.sub.2 and R.sub.3 R.sub.4 can also form a ring having 3 to 6 carbon atoms;n is an integer from 1 to 4 and can be 0 if R.sub.1 and R.sub.2 are other than hydrogen; andD is a chemical group which can be: COOR.sub.7, R.sub.7 being the hydrogen atom or a lower alkyl, CONH--R.sub.8, R.sub.8 being the hydrogen atom or a lower alkyl, CN, ##STR2## R.sub.9 being the hydrogen atom or a lower alkyl, or NHSO.sub.2 CF.sub.3, and to their addition salts.
摘要:
The invention relates to novel monoesters and diesters of 9,10-endoethano-9,10-dihydroanthracene-11,11-dicarboxylic acid.These novel monoesters and diesters correspond to the following structural chemical formula (II): ##STR1## in which R.sup.1 and R.sup.2 are identical or different and can represent H, an alkali metal or alkaline earth metal atom, a linear or branched alkyl group having from 1 to 6 carbon atoms, an alicyclic group having from 3 to 6 carbon atoms, an alkenyl group having from 2 to 6 carbon atoms, defined in their cis or trans variety, or an alkynyl group having from 2 to 6 carbon atoms, the said groups optionally being substituted by one or more functional groups such as ether, epoxide, halogeno, cyano, ester, aldehyde, ketone, aryl etc., where R.sup.1 and R.sup.2 cannot be H or ethyl simultaneously. These addition products constitute valuable intermediates for the preparation of methylidenemalonates in high yields and with a high purity.
摘要:
The present invention relates to the derivatives of formula: ##STR1## and to their tautomeric forms as well as to their addition salts and to their use in therapy, in particular for the treatment of cardiovascular diseases, especially for the treatment of hypertension, cardiac insufficiency and diseases of the arterial wall.